{
    "id": 10262,
    "fullName": "ASPSCR1 - TFE3",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ASPSCR1-TFE3 results from the fusion of ASPSCR1 and TFE3, which demonstrates oncogenic activity including autophosphorylation of Met and activation of the Erk and Pi3k/Akt signaling pathways (PMID: 17283122), increased expression of p21 and proinflammatory cytokines (PMID: 27673450), and is tumorigenic in mouse models (PMID: 25453902).  ASPSCR1-TFE3 (ASPL-TFE3) has been associated with alveolar soft part sarcomas PMID: 17283122, PMID: 25453902, PMID: 27673450).",
            "references": [
                {
                    "id": 3414,
                    "pubMedId": 17283122,
                    "title": "TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17283122"
                },
                {
                    "id": 18421,
                    "pubMedId": 27673450,
                    "title": "ASPL-TFE3 Oncoprotein Regulates Cell Cycle Progression and Induces Cellular Senescence by Up-Regulating p21.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27673450"
                },
                {
                    "id": 18422,
                    "pubMedId": 25453902,
                    "title": "Modeling alveolar soft part sarcomagenesis in the mouse: a role for lactate in the tumor microenvironment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25453902"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 79058,
        "geneSymbol": "ASPSCR1",
        "terms": [
            "ASPSCR1",
            "ASPCR1",
            "ASPL",
            "ASPS",
            "RCC17",
            "TUG",
            "UBXD9",
            "UBXN9"
        ]
    },
    "variant": "ASPSCR1 - TFE3",
    "createDate": "08/06/2015",
    "updateDate": "03/27/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 7030,
                "geneSymbol": "TFE3",
                "terms": [
                    "TFE3",
                    "bHLHe33",
                    "RCCP2",
                    "RCCX1",
                    "TFEA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 12944,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "ASPSCR1-TFE3 fusions aid the diagnosis of synovial sarcoma (NCCN.org).",
            "molecularProfile": {
                "id": 10292,
                "profileName": "ASPSCR1 - TFE3"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4239,
                "name": "alveolar soft part sarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3117,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PHA-665752 inhibited growth and HGF-dependent MET phosphorylation of a human renal cell carcinoma cell line harboring ASPSCR1-TFE3 in culture (PMID: 17283122).",
            "molecularProfile": {
                "id": 10292,
                "profileName": "ASPSCR1 - TFE3"
            },
            "therapy": {
                "id": 2162,
                "therapyName": "PHA-665752",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3414,
                    "pubMedId": 17283122,
                    "title": "TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17283122"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3175,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical study, cediranib resulted in an objective response rate of 35% and a disease control rate of 84% at 24 weeks in 43 patients with metastatic alveolar soft part sarcoma, which is primarily driven by ASPSCR1-TFE3 fusion (PMID: 23630200).",
            "molecularProfile": {
                "id": 10292,
                "profileName": "ASPSCR1 - TFE3"
            },
            "therapy": {
                "id": 1001,
                "therapyName": "Cediranib",
                "synonyms": null
            },
            "indication": {
                "id": 4239,
                "name": "alveolar soft part sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3627,
                    "pubMedId": 23630200,
                    "title": "Cediranib for metastatic alveolar soft part sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23630200"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3123,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Sutent (sunitinib) resulted in a RECIST partial response in 2 of 4 patients and RECIST stable disease in 1 patient with ASPSCR1-TFE3 fusion alveolar soft part sarcoma after 3 months of therapy (PMID: 19188185).",
            "molecularProfile": {
                "id": 10292,
                "profileName": "ASPSCR1 - TFE3"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4239,
                "name": "alveolar soft part sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3628,
                    "pubMedId": 19188185,
                    "title": "Response to sunitinib malate in advanced alveolar soft part sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19188185"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 10292,
            "profileName": "ASPSCR1 - TFE3",
            "profileTreatmentApproaches": [
                {
                    "id": 6457,
                    "name": "VEGFR3 Inhibitor",
                    "profileName": "ASPSCR1 - TFE3"
                },
                {
                    "id": 6458,
                    "name": "VEGFR2 Inhibitor",
                    "profileName": "ASPSCR1 - TFE3"
                },
                {
                    "id": 6459,
                    "name": "VEGFR1 Inhibitor",
                    "profileName": "ASPSCR1 - TFE3"
                },
                {
                    "id": 6456,
                    "name": "MET Inhibitor",
                    "profileName": "ASPSCR1 - TFE3"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}